A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours - Baruchel, S; Sharp, J R; Bartels, U (Eur J Cancer, 2009)
et al.